William Blair Cuts Earnings Estimates for LENZ Therapeutics

Key Points

• William Blair has revised its earnings estimates for LENZ Therapeutics, predicting a Q3 2025 EPS of ($0.69), down from a previous forecast of ($0.68).
• Several analysts have given positive ratings for LENZ Therapeutics, with HC Wainwright increasing the target price to $48.00 and Citigroup raising theirs to $49.00.
• LENZ Therapeutics has shown a favorable stock performance recently, with shares trading at $29.77 and a market cap of approximately $838 million.

LENZ Therapeutics, Inc. (NASDAQ:LENZ - Free Report) - Equities researchers at William Blair dropped their Q3 2025 EPS estimates for shares of LENZ Therapeutics in a research note issued on Wednesday, July 30th. William Blair analyst L. Hanbury-Brown now forecasts that the company will post earnings per share of ($0.69) for the quarter, down from their prior estimate of ($0.68). The consensus estimate for LENZ Therapeutics' current full-year earnings is ($2.18) per share. William Blair also issued estimates for LENZ Therapeutics' Q4 2025 earnings at ($0.88) EPS, FY2025 earnings at ($2.61) EPS, Q1 2026 earnings at ($0.82) EPS, Q2 2026 earnings at ($0.68) EPS, Q3 2026 earnings at ($0.57) EPS, Q4 2026 earnings at ($0.43) EPS and FY2026 earnings at ($2.50) EPS.

LENZ has been the subject of several other reports. Raymond James Financial increased their price objective on LENZ Therapeutics from $39.00 to $40.00 and gave the company an "outperform" rating in a research note on Thursday, July 31st. Citigroup reiterated a "buy" rating and set a $49.00 target price (up from $45.00) on shares of LENZ Therapeutics in a report on Thursday, July 31st. Piper Sandler began coverage on LENZ Therapeutics in a report on Monday, April 14th. They set an "overweight" rating and a $51.00 price target on the stock. Finally, HC Wainwright restated a "buy" rating and issued a $48.00 price objective (up previously from $38.00) on shares of LENZ Therapeutics in a report on Monday, July 28th. Five analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the company has a consensus rating of "Buy" and a consensus price target of $49.60.

LENZ Therapeutics Trading Up 4.5%

LENZ Therapeutics stock traded up $1.31 on Friday, hitting $30.64. 353,690 shares of the stock traded hands, compared to its average volume of 249,722. LENZ Therapeutics has a 1 year low of $16.53 and a 1 year high of $38.93. The firm has a market cap of $873.83 million, a P/E ratio of -16.09 and a beta of 0.42. The business's fifty day simple moving average is $31.05 and its 200 day simple moving average is $27.06.

LENZ Therapeutics (NASDAQ:LENZ - Get Free Report) last released its quarterly earnings results on Wednesday, July 30th. The company reported ($0.53) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.58) by $0.05. The firm had revenue of $5.00 million for the quarter, compared to the consensus estimate of $5.00 million.

Hedge Funds Weigh In On LENZ Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of the business. KLP Kapitalforvaltning AS bought a new position in LENZ Therapeutics during the 4th quarter worth $46,000. Tower Research Capital LLC TRC increased its stake in LENZ Therapeutics by 162.3% in the 4th quarter. Tower Research Capital LLC TRC now owns 1,860 shares of the company's stock worth $54,000 after acquiring an additional 1,151 shares during the last quarter. Virtus ETF Advisers LLC bought a new stake in LENZ Therapeutics during the fourth quarter worth about $67,000. Banque Transatlantique SA bought a new stake in LENZ Therapeutics during the 1st quarter valued at approximately $119,000. Finally, GAMMA Investing LLC raised its stake in LENZ Therapeutics by 5,254.1% during the 1st quarter. GAMMA Investing LLC now owns 5,836 shares of the company's stock valued at $150,000 after buying an additional 5,727 shares during the last quarter. Institutional investors and hedge funds own 54.32% of the company's stock.

LENZ Therapeutics Company Profile

LENZ Therapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.